Corporate Information – Page 7 – Alligator Bioscience

2025-05-262025-05-28

Alligator Bioscience announces Henlius receives European orphan drug designation for HLX22 in gastric cancer

Lund, Sweden – 26 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Commission has granted orphan ...

2025-05-23

Lund, Sweden, 23 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the presentation of biomarker data from its ...

2025-05-21

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2025-05-20

Lund, Sweden, 20 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical stage biotechnology company pioneering immuno-o ...

2025-05-20

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2025-05-15

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-05-12

Regulatory

Lund, Sweden, 12 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) is pleased to announce that data from its OPTIMIZE-1 clinic ...

2025-05-09

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-05-09

Lund, Sweden, 9 May 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the successful completion of the manufacture ...